Tanvex BioPharma Forging Strategic Alliance With Bora Pharmaceuticals
Combining Tanvex’s biosimilar development expertise and U.S. FDA-licensed commercial-scale facility in San Diego, California, with Bora’s extensive global CDMO capabilities, the alliance aims to provide...
Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi™ and FDA Accepts Biosimilar Biologics License Application for TX-05
FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex's Expertise in Biologics Development and Manufacturing. Tanvex BioPharma USA, Inc. (“Tanvex” or...
Tanvex CDMO Launch Empowers Advancements in Novel Biologics and Biosimilars
New biologics outsourcing solution provider leverages proven track record of Tanvex BioPharma USA Inc. to help early-stage companies bring mammalian and microbial derived biologics from...